List of Excipients in Branded Drug FAZACLO

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
Jazz Pharmaceuticals Inc	FAZACLO	clozapine	18860-101	ASPARTAME
Jazz Pharmaceuticals Inc	FAZACLO	clozapine	18860-101	CELLULOSE, MICROCRYSTALLINE
Jazz Pharmaceuticals Inc	FAZACLO	clozapine	18860-101	CITRIC ACID MONOHYDRATE
Jazz Pharmaceuticals Inc	FAZACLO	clozapine	18860-101	CROSPOVIDONE
Jazz Pharmaceuticals Inc	FAZACLO	clozapine	18860-101	DIMETHYLAMINOETHYL METHACRYLATE - BUTYL METHACRYLATE - METHYL METHACRYLATE COPOLYMER
Jazz Pharmaceuticals Inc	FAZACLO	clozapine	18860-101	FERRIC OXIDE YELLOW

FAZACLO Excipient Strategy and Commercial Opportunities

Last updated: September 24, 2026

FAZACLO is an orally disintegrating tablet (ODT) containing clozapine for treatment-resistant schizophrenia and reduction of recurrent suicidal behavior in patients with schizophrenia or schizoaffective disorder. Its commercial differentiation came from rapid oral disintegration without water, not from a novel active ingredient. The product’s excipient platform supports taste acceptability, tablet strength, low-dose content uniformity, and rapid dispersion in the mouth.

The strongest commercial opportunities are reformulated clozapine ODT products, improved taste-masked presentations, adherence-oriented packaging, and differentiated generic or 505(b)(2) products. Long-term brand exclusivity is limited because clozapine is an established molecule with generic tablets, orally disintegrating tablets, and broad prior art.

What excipients are used in FAZACLO tablets?

FAZACLO uses a conventional direct-compression ODT excipient system. The labeled inactive ingredients include aspartame, colloidal silicon dioxide, crospovidone, lactose monohydrate, magnesium stearate, mannitol, microcrystalline cellulose, and flavoring components.[1]

Excipient	Primary function	Commercial relevance
Mannitol	Diluent, mouthfeel modifier, cooling agent, sweetness	Supports palatability and rapid ODT dispersion
Microcrystalline cellulose	Compression aid and structural filler	Provides tablet hardness and mechanical integrity
Crospovidone	Superdisintegrant	Promotes rapid breakup after exposure to saliva
Lactose monohydrate	Diluent and bulking agent	Supports tablet mass and content uniformity
Aspartame	Sweetener	Reduces clozapine’s bitter taste
Flavoring	Taste masking and acceptability	Helps support chronic use
Colloidal silicon dioxide	Glidant and flow aid	Improves powder flow and manufacturing consistency
Magnesium stearate	Lubricant	Prevents sticking and improves tablet ejection

The formulation balances conflicting ODT requirements. The tablet must be hard enough to survive packaging and handling, yet porous and rapidly wettable enough to disintegrate on the tongue. Excessive lubricant can slow wetting and dissolution. Excessive compression force can increase tablet hardness while reducing disintegration performance.

How does the FAZACLO formulation support commercial differentiation?

FAZACLO’s main product advantage is administration without water. That attribute is commercially relevant for patients with treatment-resistant schizophrenia who have difficulty swallowing conventional tablets, patients in supervised-care settings, and patients whose adherence is impaired by the inconvenience of standard oral administration.

The formulation strategy has four commercial functions:

1. Rapid dispersion. Crospovidone, mannitol, and the tablet’s physical structure allow the dosage form to break apart rapidly in the oral cavity.
2. Taste management. Aspartame, flavoring, mannitol, and lactose reduce the sensory burden of clozapine.
3. Dose flexibility. The 12.5 mg, 25 mg, 100 mg, 150 mg, and 200 mg strengths support titration and maintenance dosing.[1]
4. Manufacturing scalability. Microcrystalline cellulose, colloidal silicon dioxide, and magnesium stearate are widely available and compatible with conventional tablet manufacturing.

The excipient system is therefore commercially practical but not difficult to reproduce. A competitor would face formulation-development and bioequivalence work, but the inactive ingredients themselves are not a durable barrier to entry.

What formulation patents protect FAZACLO?

FAZACLO’s principal protection was based on the product’s approved drug application, formulation know-how, trademarks, and historical market position. The excipients used in the product are established pharmaceutical materials with extensive prior art.

Potentially protectable formulation elements include:

• Specific excipient ratios;
• Tablet porosity and compression parameters;
• Disintegration time;
• Taste-masking systems;
• Flavor combinations;
• Packaging that protects the ODT from moisture;
• Manufacturing processes that improve content uniformity;
• Alternative clozapine particle-size distributions;
• Stabilized or modified-release presentations.

A formulation patent would need to distinguish the claimed combination from prior clozapine tablets and earlier ODT technologies. Claims directed only to using mannitol, crospovidone, microcrystalline cellulose, aspartame, and magnesium stearate would face substantial obviousness risk because each component is common in ODT formulations.

The stronger patent strategy is a narrow, performance-based claim. Examples include a specified disintegration profile, dissolution profile, low friability, defined taste-masking performance, or a manufacturing process that solves a documented clozapine-specific problem.

When does FAZACLO lose exclusivity?

FAZACLO has no meaningful remaining new-molecule exclusivity. Clozapine was first approved in the United States in 1989, and the drug has long been available through generic products.[2] Any historical exclusivity associated with the product’s later ODT approval has expired.

Protection category	FAZACLO position
New chemical entity exclusivity	Expired
Basic clozapine compound patents	Expired
ODT product exclusivity	Expired or commercially exhausted
Generic clozapine tablets	Available
Generic clozapine ODT products	Historically marketed by multiple manufacturers
Current brand advantage	Dosage-form recognition and established prescribing familiarity
Main residual barriers	Bioequivalence, taste, stability, packaging, pharmacovigilance, and distribution

FAZACLO’s commercial position is therefore governed by generic competition, supply reliability, product quality, and institutional purchasing rather than by a live compound patent estate.

What is the Orange Book status of FAZACLO?

FAZACLO was approved as a prescription clozapine product and historically appeared in FDA drug-product listings. The Orange Book distinguishes approved products from discontinued products and identifies patent or exclusivity information when applicable.[3]

For commercial diligence, the relevant questions are:

• Whether the reference listing remains active or has been discontinued;
• Whether any patents remain listed against the product;
• Whether the reference product is still eligible for ANDA referencing;
• Whether the proposed product is a generic ODT or a reformulated 505(b)(2) product;
• Whether inactive-ingredient differences affect bioequivalence or labeling.

The absence of an active brand product does not eliminate the opportunity to commercialize clozapine ODT. It can shift the regulatory strategy toward an ANDA referencing an approved clozapine ODT, or toward a 505(b)(2) pathway if the proposed dosage form, indication, or clinical performance differs materially from an existing reference.

Which companies are challenging FAZACLO exclusivity?

Generic competition has historically targeted clozapine in several dosage forms. The relevant competitive group includes manufacturers of:

• Conventional clozapine tablets;
• Clozapine orally disintegrating tablets;
• Hospital and institutional unit-dose products;
• Authorized generic products;
• Specialty-distributed products supporting ANC monitoring and adherence.

Because clozapine is an established generic active ingredient, the principal competitive challenge is not a single Paragraph IV campaign against a strong live patent. It is the ability to obtain FDA approval, maintain supply, meet dissolution and stability specifications, and compete within a restricted-prescribing environment.

What Paragraph IV risks exist?

Paragraph IV risk is likely to be limited for a conventional FAZACLO-equivalent product if no enforceable formulation patent remains listed. A new applicant could still face:

• Patent litigation based on a later-listed formulation patent;
• Regulatory disputes over reference-product selection;
• Bioequivalence disputes involving rapid disintegration or dissolution;
• Labeling issues tied to clozapine monitoring requirements;
• Commercial disputes over trademark or trade dress.

For a new, taste-masked, modified-release, or combination product, Paragraph IV exposure could become more relevant if the innovator obtains claims covering specific excipient ratios, dissolution performance, or delivery technology.

How strong is the FAZACLO patent estate?

The historical FAZACLO patent estate is weak as a basis for current exclusivity. The formulation uses widely available excipients, and clozapine ODT technology has broad prior art. The product’s strongest defensible assets are likely to be operational rather than patent-based.

Asset	Relative strength
Clozapine active ingredient	Low; longstanding generic availability
Conventional tablet formulation	Low
ODT dosage form	Low to moderate, depending on claim scope
Taste-masking technology	Moderate if clinically or analytically demonstrated
Moisture-protective packaging	Moderate
Manufacturing know-how	Moderate but difficult to enforce independently
Brand recognition	Moderate in the clozapine specialty market
Distribution and monitoring infrastructure	Moderate to strong operationally
Patient and prescriber familiarity	Moderate

A new entrant should not rely on broad composition-of-matter claims. The more defensible strategy is a layered portfolio covering formulation performance, packaging, manufacturing controls, and a differentiated clinical or adherence use.

What excipient changes create the best commercial opportunities?

Aspartame-free FAZACLO alternatives

Aspartame-free products could address patients with phenylketonuria and buyers seeking formulations without phenylalanine-generating sweeteners. Alternatives include sucralose, acesulfame potassium, sodium saccharin, steviol glycosides, or combinations of sweeteners and flavor modulators.

The main development challenge is clozapine’s bitterness. A simple sweetener substitution may not provide equivalent taste performance. Ion-exchange resins, polymeric taste-masking systems, coated particles, and cyclodextrin-based approaches could create stronger differentiation.

Lactose-free formulations

A lactose-free clozapine ODT could target patients who avoid lactose or institutions that prefer excipient-standardized products. Mannitol, sorbitol, isomalt, or additional microcrystalline cellulose could replace lactose, but changes in hygroscopicity, hardness, friability, and mouthfeel would require comparative development.

Sugar-free and low-calorie products

FAZACLO already relies heavily on mannitol rather than sucrose. A fully sugar-free product with a defined carbohydrate profile could support institutional formularies and patients with dietary restrictions. Labeling claims must reflect the actual excipient composition and applicable FDA requirements.

Moisture-resistant packaging

ODTs are vulnerable to humidity, especially when packed in blister systems that are opened by peeling or pushing. High-barrier aluminum-aluminum blisters, desiccant-backed bottles, and unit-dose packaging can improve stability and reduce tablet breakage.

Packaging innovation may deliver more practical value than a minor excipient change. A product that preserves tablet integrity during dispensing and supervised administration could win institutional contracts even without a materially different pharmacology.

Modified-release clozapine

Modified-release clozapine could reduce peak-related adverse effects, simplify dosing, or improve adherence. It would also create a more substantial regulatory and clinical program. The opportunity is larger than for a simple generic ODT, but so are the risks involving pharmacokinetics, seizure risk, dose conversion, and demonstration of therapeutic equivalence.

What FDA regulatory pathway applies to a new clozapine ODT?

A conventional clozapine ODT that matches an approved reference product would generally pursue an ANDA under section 505(j) of the Federal Food, Drug, and Cosmetic Act. The applicant would need to establish pharmaceutical equivalence and bioequivalence, meet current manufacturing requirements, and address clozapine-specific monitoring and labeling obligations.[4]

A 505(b)(2) application may be appropriate when the product introduces a clinically meaningful change, such as:

• A new delivery system;
• Modified release;
• A materially different dosage form;
• A new route of administration;
• A new indication;
• A formulation that cannot be adequately supported through an ANDA.

The regulatory value of the ODT depends on whether FDA treats the product as pharmaceutically equivalent to the reference product or requires additional clinical or pharmacokinetic evidence.

What manufacturing and intellectual-property barriers exist?

The principal manufacturing barriers are process control and product robustness:

• Uniform distribution of low-dose clozapine;
• Avoidance of tablet capping and friability;
• Consistent disintegration across strengths;
• Control of lubricant concentration and blending time;
• Humidity control during compression;
• Packaging protection against moisture;
• Stability of flavor and sweetener systems;
• Prevention of cross-contamination in potent-drug facilities.

Clozapine’s potent pharmacology also creates facility and cleaning-validation requirements. A manufacturer may need dedicated controls for dust containment, employee exposure, and cross-contamination.

The strongest IP opportunity is a patent family combining formulation and process claims. A commercially useful portfolio could cover a low-friability ODT, a moisture-resistant package, a defined taste-masking architecture, and a process that achieves consistent dissolution across multiple strengths.

What commercial opportunities remain for FAZACLO-like products?

The highest-value opportunities are niche products rather than broad commodity generics.

Opportunity	Market rationale	Development burden
Generic clozapine ODT	Direct substitution and familiar dosage form	Moderate
Aspartame-free ODT	Addresses phenylketonuria and excipient preferences	Moderate
Lactose-free ODT	Supports excipient-sensitive patients and institutions	Moderate
Premium taste-masked ODT	May improve adherence and caregiver acceptance	Moderate to high
Unit-dose blister product	Improves dispensing and supervised administration	Low to moderate
Modified-release clozapine	Potential adherence and tolerability benefits	High
Pediatric or geriatric ODT	Addresses swallowing and dosing needs	High
Digital adherence package	Links dispensing, monitoring, and refill management	Moderate
International clozapine ODT	Extends product life in markets with limited ODT competition	Moderate

Revenue potential depends less on total schizophrenia prevalence than on the smaller treatment-resistant population receiving clozapine. Commercial execution must account for mandatory blood-count monitoring, prescriber reluctance, specialty distribution, and patient discontinuation risk.

What patent litigation and settlement issues affect FAZACLO?

Historical litigation risk would have centered on generic entry, formulation patents, and regulatory exclusivity. For a current FAZACLO-like product, litigation exposure is more likely to arise from a new entrant’s differentiated formulation patent than from the legacy FAZACLO product itself.

A settlement involving a later formulation patent could include:

• A licensed launch date;
• Authorized generic supply;
• Restrictions on dosage strengths;
• Territory-specific rights;
• Covenants not to sue;
• Manufacturing or distribution rights.

No commercially significant settlement should be assumed without a case-specific review of court dockets, FDA listings, and executed agreements.

How does FAZACLO compare with conventional clozapine tablets?

Attribute	FAZACLO-type ODT	Conventional clozapine tablet
Water required	No	Usually yes
Swallowing burden	Lower	Higher
Taste exposure	Direct oral exposure	Lower if swallowed promptly
Excipient complexity	Higher taste and disintegration requirements	Simpler tablet architecture
Packaging sensitivity	Often higher	Generally lower
Differentiation potential	Moderate	Low
Generic substitution risk	High	Very high
Clinical value	Administration and adherence convenience	Established standard dosage form

The ODT’s economic value depends on whether patients, caregivers, prescribers, or institutions are willing to pay for administration convenience. Without strong taste performance and reliable packaging, the ODT may be treated as a generic substitute rather than a premium product.

Key Takeaways

• FAZACLO uses a conventional ODT excipient platform built around mannitol, crospovidone, microcrystalline cellulose, lactose, aspartame, flavoring, colloidal silicon dioxide, and magnesium stearate.
• The principal product advantage is water-free administration, not novel pharmacology.
• Clozapine compound exclusivity and FAZACLO’s meaningful market exclusivity have expired.
• Broad excipient claims would face substantial prior-art and obviousness risk.
• The strongest new IP opportunities involve taste masking, tablet performance, moisture-resistant packaging, and manufacturing controls.
• Aspartame-free, lactose-free, unit-dose, and improved taste-masked products offer the clearest near-term commercial opportunities.
• A conventional generic ODT would likely use an ANDA pathway; materially different delivery systems may require a 505(b)(2) application.
• Supply reliability, packaging integrity, monitoring support, and institutional distribution are more important current barriers than legacy FAZACLO patent rights.

FAQs

Can a new company launch a clozapine ODT without licensing FAZACLO?

Yes, if the product can rely on an applicable FDA regulatory pathway and does not infringe enforceable patent claims. Brand licensing is not inherently required for a generic clozapine ODT.

Is mannitol the best filler for a clozapine orally disintegrating tablet?

Mannitol is commercially attractive because it provides bulk, sweetness, cooling mouthfeel, and good ODT performance. It is not automatically optimal. Isomalt, sorbitol, lactose-free systems, or co-processed excipients may improve hardness, taste, or stability.

Can a clozapine ODT claim better adherence?

A sponsor can develop adherence data, but an adherence claim requires appropriate clinical evidence and FDA-consistent labeling. The ODT format alone does not establish improved adherence.

Does changing aspartame to sucralose create a patentable product?

Usually not by itself. Patentability would depend on the complete formulation, demonstrated technical effect, and non-obviousness over prior art.

Is modified-release clozapine a stronger commercial opportunity than FAZACLO-style ODT?

It has greater differentiation potential but requires substantially more development, pharmacokinetic validation, safety analysis, and regulatory investment than a conventional ODT.

References

1. DailyMed. (n.d.). FAZACLO- clozapine tablet, orally disintegrating. U.S. National Library of Medicine.
2. U.S. Food and Drug Administration. (n.d.). Clozapine drug products and prescribing information. FDA.
3. U.S. Food and Drug Administration. (n.d.). Approved drug products with therapeutic equivalence evaluations. FDA.
4. U.S. Food and Drug Administration. (2022). ANDA submissions: Content and format. FDA.